[go: up one dir, main page]

ES2192419T3 - Material aislado que presenta un efecto anti-organotrofico. - Google Patents

Material aislado que presenta un efecto anti-organotrofico.

Info

Publication number
ES2192419T3
ES2192419T3 ES99972922T ES99972922T ES2192419T3 ES 2192419 T3 ES2192419 T3 ES 2192419T3 ES 99972922 T ES99972922 T ES 99972922T ES 99972922 T ES99972922 T ES 99972922T ES 2192419 T3 ES2192419 T3 ES 2192419T3
Authority
ES
Spain
Prior art keywords
organotrophic
presents
effect
isolated material
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99972922T
Other languages
English (en)
Inventor
John Ernest Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocrine Pharmaceuticals Ltd
Original Assignee
Endocrine Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocrine Pharmaceuticals Ltd filed Critical Endocrine Pharmaceuticals Ltd
Application granted granted Critical
Publication of ES2192419T3 publication Critical patent/ES2192419T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Material que tiene la capacidad de reducir la masa de órganos, pudiéndose obtener dicho material mediante: la recogida de sangre venosa de ovario a partir de un mamífero hembra; la preparación de plasma venoso de ovario a partir de la sangre; y la purificación, por lo menos parcial, de dicho material a partir del plasma.
ES99972922T 1998-12-01 1999-12-01 Material aislado que presenta un efecto anti-organotrofico. Expired - Lifetime ES2192419T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9826186.0A GB9826186D0 (en) 1998-12-01 1998-12-01 Chemical compound

Publications (1)

Publication Number Publication Date
ES2192419T3 true ES2192419T3 (es) 2003-10-01

Family

ID=10843297

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99972922T Expired - Lifetime ES2192419T3 (es) 1998-12-01 1999-12-01 Material aislado que presenta un efecto anti-organotrofico.

Country Status (14)

Country Link
US (2) US7572465B1 (es)
EP (1) EP1135145B1 (es)
JP (1) JP2002531410A (es)
AT (1) ATE235910T1 (es)
AU (1) AU758592B2 (es)
CA (1) CA2353590A1 (es)
DE (1) DE69906575T2 (es)
DK (1) DK1135145T3 (es)
ES (1) ES2192419T3 (es)
GB (1) GB9826186D0 (es)
NZ (1) NZ512123A (es)
PT (1) PT1135145E (es)
WO (1) WO2000032208A2 (es)
ZA (1) ZA200104487B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014029D0 (en) * 2000-06-08 2000-08-02 Endocrine Pharmaceuticals Limi Isolated material having size-inhibitory effects on cells,tissues and organs
EP2234632B1 (en) 2008-01-10 2014-10-29 Endocrine Pharmaceuticals Limited Proteinaceous compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4734398A (en) * 1983-03-15 1988-03-29 University Of Southern California Follicular regulating protein

Also Published As

Publication number Publication date
GB9826186D0 (en) 1999-01-20
DK1135145T3 (da) 2003-06-23
ATE235910T1 (de) 2003-04-15
AU758592B2 (en) 2003-03-27
CA2353590A1 (en) 2000-06-08
WO2000032208A3 (en) 2000-10-19
EP1135145B1 (en) 2003-04-02
AU1399500A (en) 2000-06-19
DE69906575T2 (de) 2003-12-11
US7700132B2 (en) 2010-04-20
WO2000032208A2 (en) 2000-06-08
NZ512123A (en) 2003-02-28
EP1135145A2 (en) 2001-09-26
ZA200104487B (en) 2002-07-25
JP2002531410A (ja) 2002-09-24
DE69906575D1 (de) 2003-05-08
US7572465B1 (en) 2009-08-11
PT1135145E (pt) 2003-07-31
US20050244507A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
EP0987275A3 (en) Molecules that home to a selected organ or tissue in vivo and methods of identifying same
NO844017L (no) Spormerkede konjugater av metallothionein og maalsoekende biologiske aktive molekyler
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
ATE177421T1 (de) Wasserlösliches nimesulid-salz, sowie dessen verwendung zur behandlung von entzündungen
ID23666A (id) Senyawa-senyawa kimia
DE69831566T2 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69412552D1 (de) Medizinisches Instrument zur Behandlung von Sinusitis
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
ATE466072T1 (de) Bandscheibe
CA2169381A1 (en) Enhanced cross-linking of natural tissues
DE69527749D1 (de) Kugelförmige Aktivkohle zur Behandlung von Bauchentzündungen
ATE217889T1 (de) Humane antikörper gegen faktor ix/ixa
NO982721L (no) Preserverende oppl°sning
BR0010314B1 (pt) solução aquosa de conservação de tecidos e órgãos.
DE59508454D1 (de) Polymermaterial von medizinischen instrumenten und verfahren zur herstellung des polymermaterials
EE200000163A (et) Protsess kirurgiliste instrumentide puhastamiseks
ES2192419T3 (es) Material aislado que presenta un efecto anti-organotrofico.
DE69630879D1 (de) Biologisch abbaubare vorrichtung
ATE234862T1 (de) Glycoproteine mit lipidmobilisierenden eigenschaften und deren therapeutische verwendungen
TR200200278T2 (tr) Kalsilitik bileşimler
MXPA02005069A (es) Agentes de enlace especificos para t3 y metodos para su uso.
DE69726883D1 (de) Magnetotherapeutische vorrichtung
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE313329T1 (de) Disaccharidderivate zur behandlung von hyperglykämien